Myeloproliferative Disorders research hub

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

This study looks at adding a new medicine, navtemadlin, to an existing treatment, ruxolitinib, for people with myelofibrosis. It aims to see if this combination works better for those whose myelofibrosis isn't fully controlled by ruxolitinib alone.

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

This study is testing a new medicine called pelabresib alongside an existing treatment (ruxolitinib) for adults with myelofibrosis who haven't tried similar drugs before. It aims to see if this combination works better than ruxolitinib alone to help manage symptoms and spleen size.

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

This study is testing a new medicine, nuvisertib, for myelofibrosis. It aims to see if it's safe and how it works, either alone or with ruxolitinib. It's for people whose current treatments aren’t working well.

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

This study looks at a new drug, INCB057643, for people with certain blood cancers like myelofibrosis. It checks if the drug is safe, what dose works best, and if it helps by itself or when given with another medicine called ruxolitinib.

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

This study is for people already taking a medicine called bomedemstat for certain blood cancers like thrombocythemia or myelofibrosis. It aims to gather more information over a longer time about how safe and effective bomedemstat is for those who are already benefiting from it.

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

This study is testing a new medicine, IOA-244, for people with certain advanced cancers, including lymphoma and melanoma. It aims to see if the medicine is safe and if it can help the body's immune system fight cancer, both alone and with other treatments.

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

This study is looking at people living with myelofibrosis, a rare bone marrow condition, across Europe. We're gathering information on how the disease affects them and how it's treated in real life. This helps us understand the condition better and improve care for future patients.

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

This study is looking at a new combination treatment for myelofibrosis, a blood disorder. It combines a drug called Selinexor with Ruxolitinib to see if it's safe and helps people who haven't tried other similar treatments for myelofibrosis before.

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

This study looks at a new drug, selinexor, for people with a bone marrow condition called myelofibrosis. It's for those who haven't tried certain other treatments and have low to normal platelet counts. The main aim is to see if selinexor can shrink an enlarged spleen.

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

This study looks at a new medicine called Elritercept for myelofibrosis, a bone marrow condition. Researchers want to see if it's safe and effective when used alone or with another medicine called Ruxolitinib. They're also checking how it affects symptoms and red blood cell counts.

A Phase 2 Open-Label Study to Evaluate Momelotinib in combination with Luspatercept in Participants with Transfusion Dependent Primary or Secondary Myelofibrosis

This study looks at a new drug combination, Momelotinib and Luspatercept (Reblozyl), for people in the UK with myelofibrosis who need regular blood transfusions. The main goal is to see if these medicines can help people stop needing transfusions for at least 12 weeks.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ruxolitinib Tablets, 20 mg, manufactured by Sun Pharmaceutical Industries Limited, India with JAKAVI (ruxolitinib) tablets 20 mg, (each Jakavi 20 mg tablet contains 26.40 mg of ruxolitinib phosphate equivalent to 20 mg of ruxolitinib). Imported by: Novartis Biociências SA Av. Prof. Vicente Rao, 90 - São Paulo - SP CNPJ: 56.994.502/0001-30. Manufactured by: Novartis Pharma Stein AG, Stein – Switzerland, in healthy adult, human subjects under fasting condition.

This study compares a new 20mg ruxolitinib tablet from Sun Pharma with the existing Jakavi 20mg tablet. It's for healthy adults to see if the new tablet works the same way in the body when taken on an empty stomach. This helps ensure new medicines are just as effective.

RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis

This study is looking at a new way to treat myelofibrosis, a rare blood condition. It combines a drug called tamoxifen with another drug called ruxolitinib. Researchers want to see if this combination is safe and works better than current treatments. It's for adults with myelofibrosis.

A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive

This study is looking into a new treatment for myelofibrosis, a rare bone marrow condition. It compares a new drug called pelabresib, given with an existing medicine (ruxolitinib), against ruxolitinib alone. The aim is to see if the new combination can shrink the spleen and improve symptoms.

Methods of T Cell Depletion Trial (MoTD)

This study compares different ways to prevent a complication called GvHD after stem cell transplants for various blood cancers. It's looking for the best treatment plan to help patients recover well, using common medicines like Thymoglobulin, Cyclophosphamide, Cyclosporine, Sirolimus, and Mycophenolate Mofetil.

INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

This study is testing a new medication called imetelstat for people with myelofibrosis, a rare bone marrow cancer, who haven't responded well to previous treatments. It compares imetelstat to other available therapies to see if it improves how long people live.